AbbVie Sues Teva to Block Copies of Oriahnn Menstruation Drug

AbbVie Inc. alleges that copies of Oriahnn proposed by Teva Pharmaceuticals Industries Ltd. infringe two patents for the drug, used to manage heavy menstrual bleeding in some premenopausal women.

It’s taken as two daily capsules for up to 24 months, according to a complaint filed Feb. 3 in the US District Court for the District of Delaware.

One capsule is taken in the morning and includes 300 milligrams of elagolix, 1 mg of estradiol, and 0.5 mg of norethindrone; the other has 300 mg of elagolix and is taken at night.

One patent was issued in January 2021, and the ...